Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Alpha1-Proteinase Inhibitor in Pulmonary Emphysema due to Alpha-1 Antitrypsin Deficiency
2023-510030-83-00Phase 3Completed
- Sponsor
- Grifols
- Start
- Aug 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of prolastin-c liquid in alpha-1 antitrypsin deficiency emphysema (3 arms), sponsored by Grifols. Primary endpoint: Whole lung PD15 by CT densitometry. Started Aug 2024; status: completed.
02
Drugs
prolastin-c liquid
03
Conditions
alpha-1 antitrypsin deficiency emphysema
Beyond the preview
Go deeper on 2023-510030-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510030-83-00.